SCHEMBL802685

SCHEMBL802685

Cc1ccccc1-c1cc(OCCN)cc(Nc2n[nH]c3ccccc23)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.39
CDK7 P50613 1/20 0.38
ITK Q08881 1/20 0.37
FADS1 O60427 2/20 0.35
TRPA1 O75762 1/20 0.35
EGFR P00533 2/20 0.34
SRC P12931 2/20 0.34
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
MTOR P42345 1/20 0.34
PIK3CG P48736 1/20 0.34
ADRA2A P08913 2/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
APEX1 P27695 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805613 0.86 CDK7 (0.37) GRM4CDK7ITKFADS1USP2
SCHEMBL801650 0.81 FADS1 (0.41) GRM4CDK7ITKFADS1TRPA1
SCHEMBL802280 0.81 FADS1 (0.42) GRM4FADS1TRPA1EGFRMAPT
SCHEMBL13055203 0.78 CDK7 (0.35) GRM4CDK7ITKFADS1EGFR
SCHEMBL802348 0.78 FADS1 (0.40) GRM4FADS1TRPA1EGFRSRC
SCHEMBL801684 0.73 EGFR (0.39) GRM4FADS1TRPA1EGFRSRC
SCHEMBL802674 0.73 GSK3A (0.44) GRM4FADS1TRPA1EGFRSMN1; SMN2
SCHEMBL802062 0.72 CYP1A2 (0.43) EGFRSRCADRA2AALDH1A1CYP1A2
SCHEMBL802326 0.72 FADS1 (0.48) GRM4FADS1TRPA1EGFRSMN1; SMN2
SCHEMBL13962987 0.72 CYP1A2 (0.42) FADS1TRPA1MAPTUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 GRM4 3726/4885CDK7 63/4885ITK 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.